FindTrial
Sign In

Therapeutic efficacy of Epinastine Hydrochloride Eyelid Cream 0.5% in the treatment of allergic conjunctival disease.

Therapeutic efficacy of Epinastine Hydrochloride Eyelid Cream 0.5% in the treatment of allergic conjunctival disease. - Therapeutic efficacy of Epinastine Hydrochloride Eyelid Cream 0.5% in the treatment of allergic conjunctival disease.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056319
Enrollment
100
Registered
2024-11-30
Start date
2024-11-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic conjunctival disease

Interventions

0.5% epinastine topical eyelid cream antiallergic eye drops

Sponsors

Teikyo University
Lead Sponsor
Department of Ophthalmology Tsurumi University Dental Hospital, Ryogoku Eye Clinic, Fujishima Eye Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with allergic conjunctivitis disease

Exclusion criteria

Exclusion criteria: 1 Patients with a past history of ocular surgery. 2. Patient who can not use eye drops.

Design outcomes

Primary

MeasureTime frame
1.Change in subjective symptom score (JACQLQ) 2.Changes in objective symptom score (JACQLQ) 3.Changes in conjunctival injection score—

Countries

Japan

Contacts

Public ContactMimura Tatsuya

Teikyo University School of Medicine, Department of Ophthalmology

mimurat-tky@umin.ac.jp0339641211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026